Cardiol Therapeutics Inc. (CRDL) stock
CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.86−0.02 (-2.28%)
Close on Nov 20, 2026Market cap $86.48MP/E –Yield –
Cardiol Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Cardiol Therapeutics's enterprise value was $72.68M on Nov 11, 2026, against $53.26M a year earlier. Over the last 5 years it ranged from -$39.96M to $156.35M, with a median of $53.26M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $72.68M | +58.1% |
| 2025 | Dec 31, 2025 | $45.96M | -21.1% |
| 2024 | Dec 31, 2024 | $58.25M | +660.6% |
| 2023 | Dec 29, 2023 | $7.66M | – |
| 2022 | Dec 30, 2022 | -$39.96M | -190.3% |
| 2021 | Dec 31, 2021 | $44.26M | – |
See a number that looks wrong?